Dr Reddy’s Laboratories (UK) Limited v Boehringer Ingelheim International GMBH [2026] EWHC 2944 (Pat)
The Claimant, “DRL”, sought a declaration of invalidity in respect of the Defendant’s, “BI’s”, European Patent (UK) No. 1 730 131 B1 (“EP 131”), its associated SPC (the “SPC”), and European Patent (UK) No. 1 888 552 B1 (“EP 552“). BI counterclaimed for infringement.
Each of EP 131, the SPC and EP 552 were asserted by BI to protect its commercial product empagliflozin, which is an anti-diabetic medication which improves glucose control in patients with type-2 diabetes through sodium-glucose-cotransporter-2 (“SGLT2”) inhibition.
DRL’s principal attack on both patents was lack of plausibility such that the claims are insufficient. DRL also contended that EP 552 lacks industrial application.
As to EP 131, BI argued that the patent’s cascade of preferences would lead the skilled team to understand that a group of 15 preferred compounds, including empagliflozin, had been made, tested and shown to possess SGLT activity. Meade LJ rejected that argument as impermissible “detective work”, holding that the patent did not disclose that any SGLT testing had been carried out. He also rejected BI’s alternative structural or “glucose” argument, noting that it lacked support from BI’s medicinal chemistry evidence and had not been properly put to DRL’s experts.
Meade LJ also made contingent findings in case the law on plausibility changes. In particular, he found that empagliflozin’s unusual tetrahydrofuran substituent, including its size, polarity and non-planar conformation, provided positive reasons to doubt that it would possess SGLT inhibitory activity.
Although EP 131 did not plausibly disclose SGLT inhibitory activity, Meade LJ held that EP 552 nevertheless made a plausible technical contribution and was industrially applicable. A stable crystalline form of empagliflozin would facilitate testing of whether the compound had SGLT activity and therefore provided a real, non-speculative utility.
Meade LJ ultimately held: i) EP 131 was invalid for obviousness and/or insufficiency arising from lack of plausibility; ii) the SPC is invalid as a result; and iii) EP 552 was valid while in force such that DRL’s proposed activities would have infringed it had they not been restrained by the interim injunction.
Mark Vanhegan KC, Adam Gamsa and Seaghan Davey acted for the DRL parties, instructed by Mishcon de Reya LLP.